Divamics' AI Platform Advances Metabolic Disease Drug Discovery

Divamics has successfully leveraged its AI and molecular dynamics platform to advance drug discovery in metabolic diseases, announced in a press release. The platform played a crucial role in the design of BGM1812, a novel dual AMY3R/CTR receptor agonist aimed at treating obesity. This breakthrough was published in the July 2025 issue of the Journal of Medicinal Chemistry.

The AI-driven platform optimized peptide interactions to enhance receptor binding, resulting in a 50% increase in in vitro potency and significant in vivo efficacy, including notable weight loss and improved metabolic profiles. The platform's ability to provide a deep mechanistic understanding of drug-receptor interactions at an atomic level was instrumental in these achievements.

Divamics' technology has also contributed to the advancement of another candidate, BGM0504, which has been in Phase III clinical trials since 2024. These successes underscore the platform's potential to accelerate drug discovery and deliver high-quality therapeutic leads efficiently.